NASDAQ:VERA Vera Therapeutics Q1 2026 Earnings Report $34.04 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$34.11 +0.07 (+0.20%) As of 05/22/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$1.69Consensus EPS -$1.33Beat/MissMissed by -$0.36One Year Ago EPS-$0.81Vera Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.43 millionBeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time7:30AM ETUpcoming EarningsVera Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Earnings HeadlinesThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11, 2026 | finance.yahoo.comVera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8, 2026 | theglobeandmail.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceMay 4, 2026 | globenewswire.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
